A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

BACKGROUND: Transarterial chemoembolization (TACE) is a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Owing to differences in its efficacy across individuals, determining the indicators of patient response to TACE and finding approaches to reversing nonresponse...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Zicong, Zhao, Wenjing, Liu, Jibin, Zhang, Jing, Pan, Jing, Chen, Kang, Wang, Lele, Zhao, Hui, Chen, Xiaoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534656/
https://www.ncbi.nlm.nih.gov/pubmed/36213835
http://dx.doi.org/10.1155/2022/2704862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534656/
https://www.ncbi.nlm.nih.gov/pubmed/36213835
http://dx.doi.org/10.1155/2022/2704862

Ejemplares similares